Compare CRVS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRVS | NNNN |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 417.8M |
| IPO Year | 2016 | N/A |
| Metric | CRVS | NNNN |
|---|---|---|
| Price | $12.92 | $10.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.17 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 29.7K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.96 | $8.30 |
| 52 Week High | $26.95 | $54.90 |
| Indicator | CRVS | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 34.92 |
| Support Level | $12.95 | $8.30 |
| Resistance Level | $14.00 | $30.21 |
| Average True Range (ATR) | 0.76 | 1.30 |
| MACD | -0.29 | 0.50 |
| Stochastic Oscillator | 1.46 | 47.03 |
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).